NVAX
Price
$4.78
Change
-$0.07 (-1.44%)
Updated
Mar 28, 2:19 PM EST
40 days until earnings call
OCGN
Price
$1.63
Change
-$0.15 (-8.43%)
Updated
Mar 28, 2:19 PM EST
One day until earnings call
Ad is loading...

Analysis and predictions NVAX vs OCGN

Header iconNVAX vs OCGN Comparison
Open Charts NVAX vs OCGNBanner chart's image
Novavax
Price$4.78
Change-$0.07 (-1.44%)
Volume$2.61K
CapitalizationN/A
Ocugen
Price$1.63
Change-$0.15 (-8.43%)
Volume$5.9K
CapitalizationN/A
View a ticker or compare two or three
NVAX vs OCGN Comparison Chart

Loading...

NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
OCGNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
NVAX vs. OCGN commentary
Mar 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a Hold and OCGN is a Hold.

COMPARISON
Comparison
Mar 28, 2024
Stock price -- (NVAX: $4.84 vs. OCGN: $1.77)
Brand notoriety: NVAX: Notable vs. OCGN: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 40% vs. OCGN: 119%
Market capitalization -- NVAX: $677.37M vs. OCGN: $455.29M
NVAX [@Biotechnology] is valued at $677.37M. OCGN’s [@Biotechnology] market capitalization is $455.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $576.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.64B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 0 FA rating(s) are green whileOCGN’s FA Score has 0 green FA rating(s).

  • NVAX’s FA Score: 0 green, 5 red.
  • OCGN’s FA Score: 0 green, 5 red.
According to our system of comparison, OCGN is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 5 TA indicator(s) are bullish while OCGN’s TA Score has 4 bullish TA indicator(s).

  • NVAX’s TA Score: 5 bullish, 5 bearish.
  • OCGN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both NVAX and OCGN are a good buy in the short-term.

Price Growth

NVAX (@Biotechnology) experienced а +0.21% price change this week, while OCGN (@Biotechnology) price change was +43.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.86%. For the same industry, the average monthly price growth was +4.97%, and the average quarterly price growth was +88.78%.

Reported Earning Dates

NVAX is expected to report earnings on May 07, 2024.

OCGN is expected to report earnings on May 03, 2024.

Industries' Descriptions

@Biotechnology (+4.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for NVAX with price predictions.
OPEN
A.I.dvisor published
a Summary for OCGN with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
NVAX($677M) has a higher market cap than OCGN($455M). OCGN YTD gains are higher at: 208.696 vs. NVAX (0.833). OCGN has higher annual earnings (EBITDA): -80.36M vs. NVAX (-487.39M). NVAX has more cash in the bank: 569M vs. OCGN (53.5M). OCGN has less debt than NVAX: OCGN (6.48M) vs NVAX (229M). NVAX has higher revenues than OCGN: NVAX (556M) vs OCGN (0).
NVAXOCGNNVAX / OCGN
Capitalization677M455M149%
EBITDA-487.39M-80.36M607%
Gain YTD0.833208.6960%
P/E RatioN/AN/A-
Revenue556M0-
Total Cash569M53.5M1,064%
Total Debt229M6.48M3,537%
FUNDAMENTALS RATINGS
NVAX vs OCGN: Fundamental Ratings
NVAX
OCGN
OUTLOOK RATING
1..100
7319
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
7534
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVAX's Valuation (86) in the Biotechnology industry is in the same range as OCGN (99) in the null industry. This means that NVAX’s stock grew similarly to OCGN’s over the last 12 months.

NVAX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as OCGN (100) in the null industry. This means that NVAX’s stock grew similarly to OCGN’s over the last 12 months.

OCGN's SMR Rating (98) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that OCGN’s stock grew similarly to NVAX’s over the last 12 months.

OCGN's Price Growth Rating (34) in the null industry is somewhat better than the same rating for NVAX (75) in the Biotechnology industry. This means that OCGN’s stock grew somewhat faster than NVAX’s over the last 12 months.

OCGN's P/E Growth Rating (100) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that OCGN’s stock grew similarly to NVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAXOCGN
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 23 days ago
82%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 18 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
OCGNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SHXYX14.580.28
+1.96%
American Beacon Shapiro Equity Opps Y
RSCKX5.190.09
+1.76%
Victory RS Small Cap Equity R
FASMX20.350.09
+0.44%
Fidelity Asset Manager 50%
PCEKX22.23N/A
N/A
Pioneer Core Equity K
BGLUX32.71-0.12
-0.37%
Baron Global Advantage R6

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with CRSP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
+2.76%
CRSP - NVAX
47%
Loosely correlated
-1.14%
THRD - NVAX
42%
Loosely correlated
+5.35%
XNCR - NVAX
38%
Loosely correlated
+4.18%
SYRE - NVAX
38%
Loosely correlated
-1.62%
MRNA - NVAX
35%
Loosely correlated
+2.98%
More

OCGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCGN has been loosely correlated with MDGL. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if OCGN jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCGN
1D Price
Change %
OCGN100%
+2.60%
MDGL - OCGN
51%
Loosely correlated
+4.52%
ALNY - OCGN
48%
Loosely correlated
+1.55%
ARRY - OCGN
47%
Loosely correlated
+6.94%
AXON - OCGN
46%
Loosely correlated
-1.13%
CRSP - OCGN
42%
Loosely correlated
-1.14%
More